AIM ImmunoTech Inc.
AIM US00901B1052
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52% | -70% | 38% | -57% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Equels Thomas K CEO |
7.70 USD |
107 Bought |
824 USD |
12/06/2025 | 13/06/2025 |
| Equels Thomas K CEO |
8.70 USD |
103 Bought |
896 USD |
12/06/2025 | 12/06/2025 |
| Mitchell William M O |
0.03 USD |
196,851 Bought |
5,000 USD |
21/04/2025 | 11/04/2025 |
| Kellner Ted D O |
0.03 USD |
1,968,504 Bought |
50,000 USD |
21/04/2025 | 11/04/2025 |
| Equels Thomas K CEO |
0.03 USD |
1,968,504 Bought |
50,000 USD |
21/04/2025 | 11/04/2025 |
| Equels Thomas K CEO |
0.06 USD |
41,000 Bought |
2,583 USD |
04/04/2025 | 04/04/2025 |
| Rodino Peter W Iii COO |
0.09 USD |
500 Bought |
44 USD |
04/04/2025 | 04/04/2025 |
| Equels Thomas K CEO |
0.13 USD |
50,000 Bought |
6,730 USD |
05/03/2025 | 05/03/2025 |
| Equels Thomas K CEO |
0.12 USD |
44,000 Bought |
5,060 USD |
04/03/2025 | 04/03/2025 |
| Equels Thomas K CEO |
0.12 USD |
83,334 Bought |
10,000 USD |
04/03/2025 | 04/03/2025 |